BACKGROUND: The data from a previously published 12-week randomised, double-blind, placebo-controlled multicentre study on the efficacy and safety of pregabalin were analyzed for time to onset of analgesic action with neuropathic pain. PATIENTS AND METHODS: A total of 338 patients with postherpetic neuralgia or painful diabetic peripheral neuropathy were treated with flexible or fixed regimens of pregabalin at daily doses of up to 600 mg/day (n=141 and 132, respectively) or placebo (n=65). RESULTS: Under fixed dose treatment, a decrease of one full point on the 11-point numerical rating pain scale was reached on day 1, two full points on day 13, and three full points on day 23 (under flexible dose pregabalin: on days 6, 17 and 30). In both treatment arms, pain reduction was statistically significant (P=0.001, P=0.002 vs placebo, respectively). CONCLUSION: In patients with chronic neuropathic pain, the analgesic effect of both pregabalin treatment regimens was high and associated with a rapid time to onset.
RCT Entities:
BACKGROUND: The data from a previously published 12-week randomised, double-blind, placebo-controlled multicentre study on the efficacy and safety of pregabalin were analyzed for time to onset of analgesic action with neuropathic pain. PATIENTS AND METHODS: A total of 338 patients with postherpetic neuralgia or painful diabetic peripheral neuropathy were treated with flexible or fixed regimens of pregabalin at daily doses of up to 600 mg/day (n=141 and 132, respectively) or placebo (n=65). RESULTS: Under fixed dose treatment, a decrease of one full point on the 11-point numerical rating pain scale was reached on day 1, two full points on day 13, and three full points on day 23 (under flexible dose pregabalin: on days 6, 17 and 30). In both treatment arms, pain reduction was statistically significant (P=0.001, P=0.002 vs placebo, respectively). CONCLUSION: In patients with chronic neuropathic pain, the analgesic effect of both pregabalin treatment regimens was high and associated with a rapid time to onset.
Authors: Axel C Mühlbacher; Uwe Junker; Christin Juhnke; Edgar Stemmler; Thomas Kohlmann; Friedhelm Leverkus; Matthias Nübling Journal: Eur J Health Econ Date: 2014-06-21
Authors: Sheena Derry; Rae Frances Bell; Sebastian Straube; Philip J Wiffen; Dominic Aldington; R Andrew Moore Journal: Cochrane Database Syst Rev Date: 2019-01-23
Authors: Rainer Freynhagen; Miroslav Backonja; Stephan Schug; Gavin Lyndon; Bruce Parsons; Stephen Watt; Regina Behar Journal: CNS Drugs Date: 2016-12 Impact factor: 5.749
Authors: Sven Schmiedl; David Peters; Oliver Schmalz; Anke Mielke; Tanja Rossmanith; Shirin Diop; Martina Piefke; Petra Thürmann; Achim Schmidtko Journal: Front Pharmacol Date: 2019-07-25 Impact factor: 5.810